We have completed the largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients – and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organisation for Nuclear Research, while undergoing peer review at leading oncology journals: ‘Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort’.
In this real-world prospective clinical programme evaluation, a diverse population of cancer patients (n=197) were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.
At approximately six months post-treatment initiation,we observed an 84.4% Clinical Benefit Ratio (“CBR”), with nearly half of cancer patients (48.4%) reporting either no evidence of disease (32.8%) or tumour regression (15.6%).An additional 36.1% reported disease stabilisation. This means more than four out of five patients reported either improvement or stabilisation of their cancer.
These results indicate that the inexpensive and safe off-label applications of these medications could be an important complement in the treatment of cancer.
The groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel – uniting real-world clinical data, frontline medical experience and high-level epidemiologic expertise to deliver urgently needed insights in oncology.
This work was conducted byNicolas Hulscher, MPH (myself); Kelly Victory, MD; James A. Thorp, MD; Drew Pinsky, MD; Alejandro Diaz-Villalobos, MD; Peter Gillooly, MSc; Foster Coulson; Melissa Annazone; Chloe Radesi; Jessica Brooks; Peter A. McCullough, MD, MPH; and Harvey Risch, MD, PhD (Chairman of the President’s Cancer Panel).
The paper can be accessed HERE.
Hellbound and Down 